Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

carcinoma poorly differentiated

Known as: poorly differentiated carcinoma 
 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

Primary malignant neoplasm

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
A case study of an integrative genomic and experimental therapeutic approach for rare tumors: identification of vulnerabilities in a pediatric poorly differentiated carcinoma
BackgroundPrecision medicine approaches are ideally suited for rare tumors where comprehensive characterization may have… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
2014
2014
Cell size as a prognostic factor in oncocytic poorly differentiated carcinomas of the thyroid.
Histological and cytological criteria in predicting clinical outcomes in patients with oncocytic poorly differentiated carcinoma… Expand
2012
2012
Aggressive prostate cancer is prevented in ERαKO mice and stimulated in ERβKO TRAMP mice.
Previous evidence suggests soy genistein may be protective against prostate cancer, but whether this protection involves an… Expand
2011
2011
Genetic profile of adenoid cystic carcinomas (ACC) with high-grade transformation versus solid type
BackgroundACC can occasionally undergo dedifferentiation also referred to as high-grade transformation (ACC-HGT). However, ACC… Expand
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • table 2
Highly Cited
2002
Highly Cited
2002
Epidemiology of unknown primary tumours; incidence and population-based survival of 1285 patients in Southeast Netherlands, 1984-1992.
Patients with an unknown primary tumour (UPT) represent 5-10% of all new cancer patients. Data on survival and prognostic factors… Expand
Highly Cited
1997
Highly Cited
1997
Poorly differentiated carcinoma and poorly differentiated adenocarcinoma of unknown origin: favorable subsets of patients with unknown-primary carcinoma?
PURPOSE The objectives of this study were to assess clinical outcomes and prognostic factors in unselected, consecutive patients… Expand
Highly Cited
1997
Highly Cited
1997
Carcinoma of unknown primary site: treatment with 1-hour paclitaxel, carboplatin, and extended-schedule etoposide.
PURPOSE To evaluate the efficacy and toxicity of a novel chemotherapy combination that includes paclitaxel, carboplatin, and… Expand
Highly Cited
1996
Highly Cited
1996
p53 gene mutation in thyroid carcinoma.
The pattern of p53 protein expression was examined in 92 cases of thyroid carcinoma. When the cases were divided into two groups… Expand
Highly Cited
1994
Highly Cited
1994
A Novel Panel of Antibodies that Segregates Immunocytochemically Poorly Differentiated Carcinoma from Undifferentiated Carcinoma of the Thyroid Gland
The expression of bcl-2 and p53 was investigated by immunocytochemistry in combination with that of conventional structural and… Expand
Highly Cited
1992
Highly Cited
1992
Cisplatin-based combination chemotherapy in the treatment of poorly differentiated carcinoma and poorly differentiated adenocarcinoma of unknown primary site: results of a 12-year experience.
PURPOSE We previously reported excellent responses to cisplatin-based chemotherapy in a minority of patients with poorly… Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE